Physician profile
Marylin Powers
NPI 1538180534
$1,194.92
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $797 · 2020: $321 · 2021: $61.80 · 2022: $15.22.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $398.97 | 2019-2021 | |
| Allergan, INC. | $112.00 | 2019 | |
| Therapeuticsmd, INC. | $106.30 | 2020-2021 | |
| Astellas Pharma US INC | $97.02 | 2019-2020 | |
| Daiichi Sankyo INC. | $70.76 | 2019-2020 | |
| Pfizer INC. | $63.56 | 2019-2020 | |
| Lupin INC. | $57.99 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $44.31 | 2020 | |
| Avion Pharmaceuticals | $36.14 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $34.88 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.35 | 2019 | |
| Covidien LP | $27.96 | 2019 | |
| Amag Pharmaceuticals, INC. | $22.43 | 2019 | |
| Agile Therapeutics, INC. | $17.28 | 2021 | |
| Novo Nordisk INC | $16.05 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $15.63 | 2020 | |
| Coopersurgical, INC. | $15.22 | 2022 | |
| Mylan Pharmaceuticals INC. | $14.72 | 2019 | |
| Amgen INC. | $11.35 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marylin Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.